Publications
Detailed Information
Surgical management of recurrent ovarian cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Suh, Dong Hoon | - |
dc.contributor.author | Kim, Hee Seung | - |
dc.contributor.author | Chang, Suk-Joon | - |
dc.contributor.author | Bristow, Robert E. | - |
dc.creator | 김희승 | - |
dc.date.accessioned | 2018-01-24T05:58:54Z | - |
dc.date.available | 2020-04-05T05:58:54Z | - |
dc.date.created | 2018-09-06 | - |
dc.date.created | 2018-09-06 | - |
dc.date.issued | 2016-08 | - |
dc.identifier.citation | Gynecologic Oncology, Vol.142 No.2, pp.357-367 | - |
dc.identifier.issn | 0090-8258 | - |
dc.identifier.uri | https://hdl.handle.net/10371/138913 | - |
dc.description.abstract | Most patients with advanced-stage epithelial ovarian cancer will experience a relapse of disease despite a complete response after surgical cytoreduction and platinum-based chemotherapy. Treatment of recurrent ovarian cancer mainly comprises various combinations of systemic chemotherapy with or without targeted agents. The role of cytoreductive surgery for recurrent ovarian cancer is not well established. Although the literature on survival benefit of cytoreductive surgery for recurrent disease has expanded steadily over the past decade, most studies were retrospective, single-institution series with small numbers of patients. Given the balance between survival benefit and surgery-related morbidity during maximum cytoreductive surgical effort, it is essential to establish the optimal selection criteria for identifying appropriate candidates who will benefit from surgery without worsening quality of life. Three phase III randomized trials for this issue are currently underway. Herein, we present contemporary evidence supporting the positive role of cytoreductive surgery and offer selection criteria for optimal candidates for surgery in the treatment of recurrent ovarian cancer. (C) 2016 Elsevier Inc. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | en |
dc.publisher | Academic Press | - |
dc.title | Surgical management of recurrent ovarian cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.ygyno.2016.04.537 | - |
dc.citation.journaltitle | Gynecologic Oncology | - |
dc.identifier.wosid | 000380733700025 | - |
dc.identifier.scopusid | 2-s2.0-84975122026 | - |
dc.description.srnd | OAIID:RECH_ACHV_DSTSH_NO:T201604232 | - |
dc.description.srnd | RECH_ACHV_FG:RR00200001 | - |
dc.description.srnd | ADJUST_YN: | - |
dc.description.srnd | EMP_ID:A080402 | - |
dc.description.srnd | CITE_RATE:4.959 | - |
dc.description.srnd | DEPT_NM:의학과 | - |
dc.description.srnd | EMAIL:bboddi0311@snu.ac.kr | - |
dc.description.srnd | SCOPUS_YN:Y | - |
dc.citation.endpage | 367 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | 357 | - |
dc.citation.volume | 142 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Hee Seung | - |
dc.identifier.srnd | T201604232 | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | SECONDARY CYTOREDUCTIVE SURGERY | - |
dc.subject.keywordPlus | EPITHELIAL OVARIAN | - |
dc.subject.keywordPlus | TERTIARY CYTOREDUCTION | - |
dc.subject.keywordPlus | SELECTION CRITERIA | - |
dc.subject.keywordPlus | SURVIVAL BENEFIT | - |
dc.subject.keywordPlus | PREDICTIVE SCORE | - |
dc.subject.keywordPlus | 1ST RELAPSE | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | VALIDATION | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordAuthor | Recurrent ovarian cancer | - |
dc.subject.keywordAuthor | Cytoreductive surgery | - |
dc.subject.keywordAuthor | Selection criteria | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.